MAP2K7 and myeloid neoplasm: We investigated the oncogenic potential of RAS activation in vivo in NOD/SCID gamma-null (NSG) mice using CTR and NF1KO TF-1 cells lines, but not NRASG12D mutant, which represents an established model of myeloid neoplasms propagation in mice dependent on MEK activity [23, 24].